Getagraph.com logo
S&P 500
(0.31%) 5 115.99 points
Dow Jones
(0.30%) 38 353 points
Nasdaq
(0.37%) 15 986 points
Oil
(-0.95%) $83.05
Gas
(5.36%) $2.03
Gold
(0.33%) $2 355.00
Silver
(0.48%) $27.67
Platinum
(4.15%) $960.35
USD/EUR
(-0.27%) $0.932
USD/NOK
(-0.46%) $10.97
USD/GBP
(-0.59%) $0.796
USD/RUB
(1.63%) $93.37

リアルタイムの更新： NextCure Inc [NXTC]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 8.19%

最終更新日時30 4月 2024 @ 01:21
25% discount on Stockinvest.us - Use code: Podcast

-2.96% $ 1.310

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:21):

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function...

Stats
本日の出来高 94 109.00
平均出来高 286 475
時価総額 36.65M
EPS $0 ( 2024-03-21 )
次の収益日 ( $-0.450 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.580
ATR14 $0.0220 (1.64%)
Insider Trading
Date Person Action Amount type
2024-03-29 Shaw Kevin G. Buy 93 900 Employee Stock Option (Right to Buy)
2024-03-29 Richman Michael Buy 244 400 Employee Stock Option (Right to Buy)
2024-03-29 Myint Han Buy 93 900 Employee Stock Option (Right to Buy)
2024-03-29 Mayer Timothy Buy 93 900 Employee Stock Option (Right to Buy)
2024-03-29 Langermann Sol Buy 93 900 Employee Stock Option (Right to Buy)
INSIDER POWER
100.00
Last 94 transactions
Buy: 6 167 538 | Sell: 82 463

ボリューム 相関

長: -0.07 (neutral)
短: -0.22 (neutral)
Signal:(55.764) Neutral

NextCure Inc 相関

10 最も正の相関
10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

NextCure Inc 相関 - 通貨/商品

The country flag -0.06
( neutral )
The country flag -0.15
( neutral )
The country flag 0.00
( neutral )
The country flag -0.10
( neutral )
The country flag 0.74
( moderate )
The country flag 0.25
( neutral )

NextCure Inc 財務諸表

Annual 2023
収益: $0
総利益: $-3.68M (0.00 %)
EPS: $-2.25
FY 2023
収益: $0
総利益: $-3.68M (0.00 %)
EPS: $-2.25
FY 2022
収益: $0
総利益: $-4.48M (0.00 %)
EPS: $-2.50
FY 2021
収益: $0.00
総利益: $0.00 (0.00 %)
EPS: $-2.51

Financial Reports:

No articles found.

NextCure Inc

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。